Abstract
COLO 205 is a cell line derived from a human colon carcinoma with high degradative activity towards extracellular matrix (ECM). It has been shown that COLO 205 cells produce matrix metalloproteinases (MMPs). MMPs are a family of enzymes known to degrade components of the ECM and have been implicated in tumor invasion. In the present study, we have analyzed the multiple effects of chemically modified tetracyclines (CMTs) on the expression and activity of MMPs secreted by COLO 205 cells in vitro with the aim of evaluating these compounds for potential use in management of invasive tumors. Because COLO 205 cells can degrade an interstitial ECM in serum-free medium in vitro, we have been able to compare the effects of the tetracyclines on this measure of invasive activity with their effects on proteinase expression and activity. We demonstrate here that one of the chemically modified tetracyclines, 6-deoxy-6-demethyl- 4-de(dimethylamino)tetracycline (CMT-3) can effectively inhibit ECM degradation mediated by COLO 205 cells or their conditioned medium. Gelatin zymography and immunoblots show that CMT-3 has the ability to inhibit release of MMP-2 into conditioned medium as well as to inhibit MMP-2 gelatinolytic activity, which correlates with the results from ECM degradation assays. On the basis of our findings with COLO 205 cells we have expanded our evaluation of the tetracyclines to include effects on a genetically engineered line of MDA-MB-231 breast tumor cells overexpressing MMP-9 at levels over tenfold those of the parent cell line, and on three human prostate tumor cell lines, LNCaP, DU-145, and PC-3. We show here that CMT-3 displays multiple modes of action inhibiting MMP activity, reducing levels of MMP expression, and exhibiting selective cytotoxicity towards some of the tumor cell lines.
Keywords: Tumor invasive, modified tetracyclines, colo 205, matrix metalloprotinases, plasma proteinases, multiwell microplates, zymographic analysis, radiolabeled ECM, chromogenic coupled enzyme assay, casein impregnated gels, immunoreactive MMP 1, Densitometric scans
Current Medicinal Chemistry
Title: Inhibition of Tumor Cell Invasiveness by Chemically Modified Tetracyclines
Volume: 8 Issue: 3
Author(s): Y. Gu, M. H. Lee, J. E. Roemer, L. Musacchia, M. L. Golub and R. S. Simon
Affiliation:
Keywords: Tumor invasive, modified tetracyclines, colo 205, matrix metalloprotinases, plasma proteinases, multiwell microplates, zymographic analysis, radiolabeled ECM, chromogenic coupled enzyme assay, casein impregnated gels, immunoreactive MMP 1, Densitometric scans
Abstract: COLO 205 is a cell line derived from a human colon carcinoma with high degradative activity towards extracellular matrix (ECM). It has been shown that COLO 205 cells produce matrix metalloproteinases (MMPs). MMPs are a family of enzymes known to degrade components of the ECM and have been implicated in tumor invasion. In the present study, we have analyzed the multiple effects of chemically modified tetracyclines (CMTs) on the expression and activity of MMPs secreted by COLO 205 cells in vitro with the aim of evaluating these compounds for potential use in management of invasive tumors. Because COLO 205 cells can degrade an interstitial ECM in serum-free medium in vitro, we have been able to compare the effects of the tetracyclines on this measure of invasive activity with their effects on proteinase expression and activity. We demonstrate here that one of the chemically modified tetracyclines, 6-deoxy-6-demethyl- 4-de(dimethylamino)tetracycline (CMT-3) can effectively inhibit ECM degradation mediated by COLO 205 cells or their conditioned medium. Gelatin zymography and immunoblots show that CMT-3 has the ability to inhibit release of MMP-2 into conditioned medium as well as to inhibit MMP-2 gelatinolytic activity, which correlates with the results from ECM degradation assays. On the basis of our findings with COLO 205 cells we have expanded our evaluation of the tetracyclines to include effects on a genetically engineered line of MDA-MB-231 breast tumor cells overexpressing MMP-9 at levels over tenfold those of the parent cell line, and on three human prostate tumor cell lines, LNCaP, DU-145, and PC-3. We show here that CMT-3 displays multiple modes of action inhibiting MMP activity, reducing levels of MMP expression, and exhibiting selective cytotoxicity towards some of the tumor cell lines.
Export Options
About this article
Cite this article as:
Gu Y., Lee H. M., Roemer E. J., Musacchia L., Golub L. M. and Simon S. R., Inhibition of Tumor Cell Invasiveness by Chemically Modified Tetracyclines, Current Medicinal Chemistry 2001; 8 (3) . https://dx.doi.org/10.2174/0929867013373642
DOI https://dx.doi.org/10.2174/0929867013373642 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
RUNX2 and Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Design of NAALADase Inhibitors A Novel Neuroprotective Strategy
Current Medicinal Chemistry Effective Treatment of Human Lung Cancer by Targeting Tissue Factor with a Factor VII-Targeted Photodynamic Therapy
Current Cancer Drug Targets Role of Platelets in Angiogenesis in Health and Disease
Current Angiogenesis (Discontinued) In Vitro and In Vivo Antimetastatic Effects of ZSTK474 on Prostate Cancer DU145 Cells
Current Cancer Drug Targets Mitochondrial Trifunctional Protein Defects: Molecular Basis and Novel Therapeutic Approaches
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Role of the Calcium-Sensing Receptor in Human Pathophysiology
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Editorial [Hot topic: Prostate Cancer Therapy (Guest Editors: N. Sharifi and J.B. Aragon-Ching)]
Anti-Cancer Agents in Medicinal Chemistry Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors
Current Gene Therapy Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors
Current Diabetes Reviews Cancer Chemoprevention Drug Targets
Current Drug Targets Adverse Effects of Statins - Myths and Reality
Current Pharmaceutical Design A Novel Polyarginine Containing Smac Peptide Conjugate that Mediates Cell Death in Tumor and Healthy Cells
Medicinal Chemistry Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition Second Generation Taxanes: from the Natural Framework to the Challenge of Drug Resistance
Current Medicinal Chemistry - Anti-Cancer Agents Antagonists of Growth Hormone-Releasing Hormone in Oncology
Combinatorial Chemistry & High Throughput Screening New Bioactive Metabolites from the Marine-derived Fungi Aspergillus
Mini-Reviews in Medicinal Chemistry The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets The Use of DNA Microarray in the Pharmacogenetics of Antidepressants: Guidelines for a Targeted Approach
Current Genomics